Madrigal
🇺🇸 NASDAQ:MDGL
•
Dec 31, 2024
Madrigal Q4 2024 Earnings Report
Madrigal reported increased revenue driven by Rezdiffra despite a net loss for Q4 2024.
Key Takeaways
Madrigal Pharmaceuticals reported net revenue of $103.3 million for Q4 2024 driven by Rezdiffra sales. The company incurred a net loss of $59.4 million due to high operating expenses related to Rezdiffra's commercial launch. Cost of sales was reported at $3.4 million for the quarter.
Net revenue of $103.3 million driven by Rezdiffra sales.
Net loss of $59.4 million for Q4 2024.
Operating expenses of $170.3 million, mainly due to Rezdiffra's commercial launch.
Cost of sales reported at $3.4 million for the quarter.
Madrigal Revenue
Madrigal EPS
Madrigal Revenue by Segment
Forward Guidance
Madrigal plans to expand its presence in the MASH market through Rezdiffra sales and anticipated European approval.
Positive Outlook
- Anticipated European approval for Rezdiffra in mid-2025.
- Potential launch in Germany as the first country in Europe.
- Continued positive data from the MAESTRO-NAFLD-1 trial.
- Strong market position for treating F2 to F4c MASH patients.
- Growing body of evidence supporting Rezdiffra's efficacy.
Challenges Ahead
- High operating expenses impacting profitability.
- Continued net losses reported despite revenue growth.
- Significant cost of sales incurred during the quarter.
- Ongoing R&D expenses for late-stage clinical trials.
- Potential challenges with European regulatory approvals.